May 14th 2024
The company reported that statistically significant data was found supporting ANX007’s ability to provide vision loss protection in patients with geographic atrophy.
Pegcetacoplan shows increasing beneficial effects after 30 months of continuous treatment for GA
August 2nd 2023Data from the 30 month GALE extension study indicated that continuous treatment with pegcetacoplan injection showed increasing beneficial effects over that timeframe in patients with geographic atrophy (GA).